Public Health and General Cancer Register de La Somme, Jules Verne University, CHU Amiens, 80000, Amiens, France.
Laboratory of Biochemistry, Jules Verne University, CHU Amiens, 80000, Amiens, France.
Int Urol Nephrol. 2021 Jan;53(1):59-67. doi: 10.1007/s11255-020-02604-w. Epub 2020 Aug 12.
Biomarkers for the diagnosis and monitoring treatment response of kidney cancer are urgently needed. Neutrophil gelatinase-associated lipocalin (NGAL) is a relevant urinary biomarker for the diagnosis of a wide variety of acute and chronic kidney diseases. Its potential utility as a prognostic marker of kidney cancer is largely unknown and, therefore, was the subject of this investigation.
A retrospective study was done on 50 kidney tumor patients (urine samples prospectively collected before nephrectomy between 2004 and 2012, stored at Biobank Resource Center). The specificity, sensitivity and the predictive value of NGAL were determined for progression-free and disease-specific survival after nephrectomy in renal cell carcinoma (particularly, the clear cell renal cell carcinoma (ccRCC)). Urinary NGAL concentration (u-NGAL) was determined by CMIA technique (ARCHITECT® urine NGAL essay/ABBOTT).
Out of the 50 kidney tumor patients, 40 had clear cell carcinoma with a median u-NGAL excretion of 1.4 (IQR: 5.76) ng/mg urinary creatinine (Ucr). u-NGAL was correlated to tumor stage (p = 0.005), and Fuhrman grade (p = 0.0002). Multivariate Cox regression analysis showed a significant association between u-NGAL excretion and clear cell renal cell carcinoma progression free survival and disease specific survival (p = 0.002; p = 0.0001).
Urinary NGAL was significantly associated with the stage and the grade of kidney cancer. u-NGAL excretion could be considered as a potential biomarker to identify ccRCC patients with the more pejorative outcomes.
迫切需要用于诊断肾癌和监测治疗反应的生物标志物。中性粒细胞明胶酶相关脂质运载蛋白（NGAL）是诊断各种急性和慢性肾脏疾病的相关尿生物标志物。其作为肾癌预后标志物的潜在效用在很大程度上尚不清楚，因此这是本研究的主题。
对 50 例肾肿瘤患者（2004 年至 2012 年间前瞻性采集的肾切除术前尿液样本，储存在生物库资源中心）进行了回顾性研究。确定了 NGAL 在肾细胞癌（特别是透明细胞肾细胞癌（ccRCC））肾切除术后无进展和疾病特异性生存中的特异性、敏感性和预测值。通过 CMIA 技术（ARCHITECT®尿液 NGAL 测定法/ABBOTT）测定尿 NGAL 浓度（u-NGAL）。
在 50 例肾肿瘤患者中，有 40 例为透明细胞癌，u-NGAL 排泄中位数为 1.4（IQR：5.76）ng/mg 尿肌酐（Ucr）。u-NGAL 与肿瘤分期（p=0.005）和 Fuhrman 分级（p=0.0002）相关。多变量 Cox 回归分析显示，u-NGAL 排泄与透明细胞肾细胞癌无进展生存和疾病特异性生存显著相关（p=0.002；p=0.0001）。
尿 NGAL 与肾癌的分期和分级显著相关。u-NGAL 排泄可被认为是识别 ccRCC 患者预后较差的潜在生物标志物。
